Diamedica Therapeutics Inc (DMAC)

$4.03

+0.18

(+4.68%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $3.80
    $4.07
    $4.03
    downward going graph

    5.71%

    Downside

    Day's Volatility :6.63%

    Upside

    0.98%

    downward going graph
  • $1.94
    $4.07
    $4.03
    downward going graph

    51.91%

    Downside

    52 Weeks Volatility :52.38%

    Upside

    0.98%

    downward going graph

Returns

PeriodDiamedica Therapeutics IncIndex (Russel 2000)
3 Months
57.42%
0.0%
6 Months
31.27%
0.0%
1 Year
21.02%
0.0%
3 Years
-4.05%
-22.3%

Highlights

Market Capitalization
169.3M
Book Value
$1.25
Earnings Per Share (EPS)
-0.51
Wall Street Target Price
7.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-23.54%
Return On Equity TTM
-35.18%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-22.4M
Diluted Eps TTM
-0.51
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.62
EPS Estimate Next Year
-0.76
EPS Estimate Current Quarter
-0.16
EPS Estimate Next Quarter
-0.16

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Diamedica Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 73.7%

Current $4.03
Target $7.00

Technicals Summary

Sell

Neutral

Buy

Diamedica Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Diamedica Therapeutics Inc
Diamedica Therapeutics Inc
24.0%
31.27%
21.02%
-4.05%
44.44%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Diamedica Therapeutics Inc
Diamedica Therapeutics Inc
NA
NA
NA
-0.62
-0.35
-0.24
NA
1.25
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Diamedica Therapeutics Inc
Diamedica Therapeutics Inc
Buy
$169.3M
44.44%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Diamedica Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 13.0K → 30.83M (in $), with an average increase of 91.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -5.16M → -5.11M (in $), with an average increase of 0.4% per quarter

  • Vs REGN

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 16.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 73.2%

Institutional Holdings

  • Cooperman Leon G

    3.28%

  • Vanguard Group Inc

    2.38%

  • First Manhattan Co. LLC

    1.96%

  • PARAGON Assoc & PARAGON Assoc II JV

    1.13%

  • Bleichroeder LP

    0.89%

  • Geode Capital Management, LLC

    0.56%

Company Information

diamedica therapeutics is a clinical-stage biopharmaceutical company that is developing innovative treatments where there is significant unmet clinical need or where no current therapies are available with the focus on neurological and kidney diseases. for more information please visit www.diamedica.com.

Organization
Diamedica Therapeutics Inc
Employees
18
CEO
Mr. Dietrich John Pauls MBA
Industry
Health Technology

Discover More

FAQs